KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Return on Equity (2016 - 2025)

Novavax (NVAX) has 15 years of Return on Equity data on record, last reported at 3.1% in Q4 2025.

  • For Q4 2025, Return on Equity fell 342.0% year-over-year to 3.1%; the TTM value through Dec 2025 reached 3.1%, down 342.0%, while the annual FY2025 figure was 1.17%, 145.0% down from the prior year.
  • Return on Equity reached 3.1% in Q4 2025 per NVAX's latest filing, up from 5.74% in the prior quarter.
  • Across five years, Return on Equity topped out at 9.2% in Q1 2022 and bottomed at 31.8% in Q4 2021.
  • Average Return on Equity over 5 years is 2.04%, with a median of 0.48% recorded in 2024.
  • Peak YoY movement for Return on Equity: crashed -3066bps in 2021, then surged 3290bps in 2022.
  • A 5-year view of Return on Equity shows it stood at 31.8% in 2021, then skyrocketed by 103bps to 1.1% in 2022, then fell by -29bps to 0.78% in 2023, then crashed by -58bps to 0.33% in 2024, then tumbled by -1050bps to 3.1% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 3.1% in Q4 2025, 5.74% in Q3 2025, and 22.24% in Q2 2025.